Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:aimsTo |
discover new medicines from fungal genomes
|
| gptkbp:CEO |
gptkb:Gregory_Verdine
|
| gptkbp:collaboratesWith |
GlaxoSmithKline
|
| gptkbp:focusesOn |
genomics
drug discovery |
| gptkbp:foundedYear |
2017
|
| gptkbp:founder |
gptkb:Gregory_Verdine
|
| gptkbp:fundedBy |
gptkb:Invus
gptkb:Qiming_Venture_Partners gptkb:Foresite_Capital gptkb:WuXi_AppTec gptkb:Samsara_BioCapital gptkb:Sofinnova_Investments gptkb:ARCH_Venture_Partners gptkb:Blue_Pool_Capital Section 32 GlaxoSmithKline GV (formerly Google Ventures) Bail Capital Merck Global Health Innovation Fund |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
LifeMine Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:specializesIn |
fungal genomics
natural product drug discovery |
| gptkbp:technology |
genome mining
|
| gptkbp:website |
https://www.lifeminetx.com/
|
| gptkbp:bfsParent |
gptkb:Gregory_Verdine
|
| gptkbp:bfsLayer |
6
|